KRAS and lung cancer: Collectively, our data suggest that the combination of SHP2 and TGFβ inhibitors is effective at reversing SHP2 inhibitor-induced senescence and decreasing survival in KRAS mutant lung cancer models, likely independent of apoptotic mechanisms.